| Literature DB >> 30809514 |
Andrew L Schwaderer1, Rupesh Raina2, Anshika Khare3, Fayez Safadi3, Sharon M Moe4, Kirsten Kusumi2,3.
Abstract
Background: Urinary stones are affecting more children, and pediatric stone formers have unique pathophysiology compared to adults. While adult stone formers are most frequently male, children have an age dependent sex prevalence. Under 10 years, a majority of stone formers are boys; adolescent stone formers are mostly female. Previous adult studies have shown that stone composition is influenced by the sex and age of the stone former. Thus, we hypothesize that female and male stone forming children will also have sex and age specific stone phenotypes.Entities:
Keywords: age; kidney stones; pediatrics; sex; urolithiasis
Year: 2019 PMID: 30809514 PMCID: PMC6379338 DOI: 10.3389/fped.2019.00032
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Presentation.
| Age (years) | 12.9 ± 2.8 | 14 (11,15) | 11.7 ± 2.8 | 12 (11,14) | Mann- Whitney | |
| −0.25 ± 1.80 | 0.17 (−0.8, 0.8) | 0.73 ± 1.34 | 0.83 (−0.2, 1.8) | Mann-Whitney | ||
| ∧Weight z-score | 0.67 ± 1.43 | 1.0 (−0.2, 1.7) | 0.96 ± 1.61 | 0.9 (−0.5, 2.4) | Mann- Whitney | 0.60 |
| ∧BMI z-score | 0.91 ± 1.16 | 1.1 (1.2, 1.8) | 0.50 ± 1.60 | 0.3 (−1.0, 2.2) | 0.25 | |
| Hematuria | 12 | 15 | 9 | 17 | Chi-square | 0.75 |
| Flank pain | 32 | 39 | 12 | 22 | Chi-square | |
| Abd pain | 44 | 54 | 32 | 59 | Chi-square | 0.52 |
| Nausea | 29 | 35 | 18 | 33 | Chi square | 0.80 |
| Vomiting | 28 | 34 | 12 | 22 | Chi square | 0.11 |
| Fever | 5 | 6 | 5 | 9 | Fisher exact | 0.52 |
| Dysuria | 8 | 10 | 6 | 11 | Chi square | 0.76 |
| Back pain | 12 | 15 | 7 | 13 | Chi square | 0.78 |
| Dilated collecting system | 21 | 25 | 8 | 15 | Chi square | 0.13 |
| Furosemide | 2 | 2 | 2 | 4 | Fisher exact | 1.00 |
| Topiramate | 2 | 2 | 0 | 0 | Fisher exact | 0.52 |
| Fracture hx without comorbidities | 7 | 8.5 | 4 | 7.4 | Chi square | 0.82 |
| Family hx of urinary stones | 53 | 65 | 35 | 64 | Chi square | 1.00 |
The n for height, weight and BMI z-score was 49 females and 27 males,
hydronephrosis or pelvocaliectasis on CT or US.
Significant p-values are indicated in Bold.
Evaluation.
| CT | 55 | 67 | 31 | 57 | Chi-square | 0.25 |
| US | 23 | 28 | 11 | 20 | Chi-square | 0.21 |
| X-ray | 26 | 32 | 12 | 22 | Chi-square | 0.23 |
| Serum BMP | 63 | 77 | 44 | 81 | Chi-square | 0.51 |
| Serum calcium | 60 | 73 | 42 | 78 | Chi-square | 0.54 |
| Serum phosphorous | 15 | 18 | 13 | 24 | Chi square | 0.41 |
| Serum uric acid | 4 | 5 | 6 | 11 | Fisher exact | 0.19 |
| Serum PTH | 2 | 2 | 5 | 9 | Fisher exact | 0.11 |
| Serum 25 Vitamin D | 10 | 12 | 13 | 24 | Chi square | 0.07 |
| 24 h urine stone risk panel (Litholink) | 30 | 37 | 25 | 46 | Chi square | 0.26 |
| Stone analysis | 13 | 16 | 10 | 19 | Chi square | 0.69 |
| Pediatric Urology referral | 57 | 70 | 37 | 69 | Chi-square | 0.89 |
| Pediatric Nephrology referral | 14 | 17 | 14 | 26 | Chi-square | 0.21 |
Lab results.
| Serum Na+ | 133–145 | 138 ± 3 | 139 (137, 140) | 63 | 139(137, 141) | 138 ± 3 | 44 | MW | 0.94 |
| Serum K+ | 3.3–5.1 | 3.9 ± 0.6 | 3.9 (3.7, 4.1) | 63 | 4.0 ± 0.9 | 4.0 (3.6, 4.2) | 44 | MW | 0.49 |
| Serum Cl− | 96–108 | 105 ± 3 | 105 (103, 106) | 63 | 105 ± 3 | 104 (103, 107) | 44 | 0.58 | |
| Serum CO2 | 22–29 | 23.9 ± 2.5 | 23.9 (22.1, 26.1) | 59 | 24.1 ± 3.0 | 24.0 (21.8, 26.7) | 43 | 0.77 | |
| BUN | 4–19 | 11.1 ± 4.2 | 10 (9, 13) | 63 | 12.2 ± 2.7 | 12 (10, 14) | 44 | MW | |
| Creatinine | 0.4–1 | 0.83 ± 1.2 | 0.7 (0.6, 0.8) | 63 | 0.67 ± 0.22 | 0.6 (0.5, 0.7) | 44 | MW | 0.19 |
| Serum BUN/creat | 16.6 ± 6.5 | 16 (12, 20) | 63 | 19.8 ± 6.3 | 19 (16, 24) | 44 | |||
| Serum Ca++ | 7.6–11 | 9.32 ± 0.50 | 9.3 (9.0, 9.7) | 60 | 9.35 ± 0.46 | 9.3 (9.0, 9.8) | 42 | MW | 0.79 |
| Serum Phos | 2.7–4.5 | 4.3 ± 0.57 | 4.4 (4.1, 4.8) | 15 | 4.4 ± 0.51 | 4.4 (4.1, 4.7) | 13 | 0.77 | |
| Serum PTH | 15–65 | 45.5 ± 31.8 | 45.5 (23, 68) | 2 | 33.8 ± 18.5 | 34 (17.5, 50) | 5 | MW | 0.57 |
| Serum Vit D | 20–50 | 26.4 ± 9.5 | 29.5 (18.5, 29.5) | 10 | 28.9 ± 11.6 | 29 (20, 35) | 13 | MW | 0.79 |
| Uric acid | 3–7 | 6.1 ± 1.7 | 6 (5, 8) | 4 | 5.2 ± 1.5 | 5 (4, 7) | 6 | MW | 0.26 |
| Urine volume | >1 | 0.96 ± 0.49 | 0.85 (0.58, 1.21) | 30 | 1.02 ± 0.58 | 0.86 (0.59, 1.29) | 25 | MW | 0.89 |
| Urine Ca++ | < 4 | 2.87 ± 1.63 | 2.6 (1.6, 3.7) | 30 | 3.36 ± 2.02 | 3.0 (2.1, 4.0) | 25 | MW | 0.41 |
| Urine Cit | >180 m >250 f | 622 ± 274 | 549 (246, 749) | 30 | 562 ± 173 | 571 (428, 703) | 24 | 0.33 | |
| Urine Ox | < 40 | 33.7 ± 13.3 | 31.2 (25.0, 40.6) | 30 | 40.3 ± 16.0 | 38.3 (28.1, 49.3) | 24 | MW | 0.09 |
| CaOx SS | 6–10 | 7.67 ± 3.67 | 8.3 (5.1, 9.5) | 30 | 8.75 ± 3.64 | 8.2 (6.5, 10.5) | 25 | 0.28 | |
| CaPhos SS | 0.5–2 | 2.11 ± 1.29 | 2.4 (0.7, 3.1) | 30 | 2.67 ± 1.55 | 2.5 (1.1, 3.8) | 25 | MW | 0.12 |
| Urine Sul | 20–80 | 30.48 ± 10.65 | 32.77 (22.75, 37.87) | 30 | 37.18 ± 15.32 | 35.4 (24.39, 48.57) | 24 | 0.08 | |
| UUN | 6–14 | 7.76 ± 2.43 | 8.03 (6.21, 9.06) | 30 | 9.32 ± 3.73 | 8.23 (6.81, 11.32) | 24 | 0.09 | |
| Urine PCR | 8–14 | 0.97 ± 0.24 | 0.95 (0.82, 1.12) | 30 | 1.18 ± 0.45 | 1.08 (0.83, 1.44) | 25 | MW | 0.08 |
| UA: pH | 5–7.5 | 6.3 ± 0.9 | 6 (6, 7) | 64 | 6.5 ± 1.1 | 6 (6, 7) | 44 | MW | 0.34 |
| UA: SG | 1–1.035 | 1.019 ± 0.009 | 1.02 (1.01, 1.03) | 66 | 1.022 ± 0.006 | 1.02 (1.02, 1.03) | 46 | 0.07 | |
| UA: +LE | Neg | 23 | 33 | 69 | 2 | 4 | 46 | Fisher exact | |
| UA: +nit | Neg | 2 | 3 | 69 | 0 | 0 | 46 | Fisher exact | 0.52 |
| UA: +hgb | Neg | 55 | 80 | 69 | 39 | 85 | 46 | Fisher exact | 0.48 |
| UA: +prot | Neg | 33 | 48 | 69 | 20 | 43 | 46 | Chi square | 0.36 |
Results, Mean ± Std Dev for parametric and Median (25, 75%) for non-parametric data. Serum labs: Na.
Percent of patients with metabolic findings.
| Height z-score < −1 | 11/49 | 22 | 2/27 | 7 | Fisher exact | 0.12 |
| Bicarbonate < 22 meq/dl | 11/58 | 19 | 12/43 | 28 | Chi square | 0.29 |
| Calcium >10.5 mg/dl | 1/60 | 2 | 0/42 | 0 | Fisher exact | 1.00 |
| Vitamin D >50 ng/ml | 0/10 | 0 | 1/13 | 8 | Fisher exact | 1.00 |
| GFR < 90 | 16/41 | 39 | 7/24 | 29 | Chi square | 0.46 |
| GFR>140 | 4/41 | 10 | 2/24 | 8 | Fisher exact | 1.00 |
| Hypercalciuria (>4 mg/kg/day) | 5/30 | 17 | 6/24 | 25 | Fisher exact | 0.51 |
| Hyperoxaluria (>40 mg/1.73 m2/day) | 7/30 | 23 | 11/24 | 46 | Fisher exact | 0.15 |
| Hypocitraturia (< 180 mg/1.73 m2/day) | 1/30 | 3 | 0/24 | 0 | Chi square | 1.00 |
Figure 1The correlations between height z-score with serum calcium (mg/dl) (left), serum bicarbonate (mEq/L) (middle), and eGFR (ml/min/1.73 m2) (right) for all patients (top), females (middle), and males (bottom). There was no significant correlation for any of the comparisons. Sixty-four patients (43 females and 24 males) had both a height z-score and serum calcium measured, 65 patients (41 females and 24 males) had both a height z-score and serum bicarbonate measured and 65 (41 females and 24 males) patients had both a height z-score and eGFR). Serum calcium in mg/dl, eGFR in mil/min/1.73 m2 and bicarbonate in mEq/L. The dashed lines represent 95% confidence intervals.
Figure 2The correlations between eGFR with serum BUN/creatinine ratio (left) and serum bicarbonate (mEq/L) (right), for all patients (top), females (middle), and males (bottom). eGFR had a significant direct correlation with the BUN/creatinine ratio for all patients, females, and males. There was no significant correlation between the eGFR and serum bicarbonate. Sixty-five patients (41 males and 24 females) had both a height z-score and serum BUN/creatinine ratio measured and 63 patients (40 females and 23 males) had both an eGFR and serum bicarbonate. Serum BUN/creatinine in mg/mg, eGFR in mil/min/1.73 m2 and bicarbonate in mEq/L. The dashed lines represent 95% confidence intervals.
Figure 3The correlations between urine markers of dietary protein intake consisting of urine protein catabolic rate (PCR) (left), urine urea nitrogen (UUN) (middle), and urine sulfate (SUL) (right), compared to eGFR (top), serum BUN (middle), and serum BUN/creatinine (bottom). The correlation between PCR and BUN just missed significance while there was a significant correlation between UUN and eGFR along with SUL and eGFR.
Clinical course, procedures, and treatment.
| >1 stone episodes | 19 | 23 | 11 | 20 | 0.69 |
| Hospitalization | 29 | 35 | 19 | 35 | 1.00 |
| Multiple ED visits | 14 | 17 | 14 | 26 | 0.21 |
| ≥1 procedure | 17 | 21 | 8 | 15 | 0.38 |
| Stent placement | 8 | 10 | 1 | 2 | 0.09 |
| Pyelogram | 8 | 10 | 3 | 6 | 0.52 |
| Lithotripsy | 9 | 11 | 6 | 11 | 1.00 |
| Ureteroscopy | 9 | 11 | 3 | 6 | 0.36 |
| Basket | 4 | 5 | 1 | 2 | 0.35 |
| Tamulosin prescription | 38 | 46 | 22 | 41 | 0.60 |
| Hydrochlorothiazide prescription | 2 | 2 | 3 | 6 | 0.39 |
| Citrate prescription | 6 | 7 | 4 | 7 | 1.00 |
| Dietary recommendations | 55 | 67 | 40 | 74 | 0.38 |
| 55 | 67 | 39 | 72 | 0.52 | |
| 17 | 21 | 2 | 4 | ||
| 2 | 2 | 1 | 2 | 1.00 | |
| 22 | 27 | 15 | 28 | 0.92 | |
| 3 | 4 | 4 | 7 | 0.43 | |
Precedes a significant p value;
denotes increasing;
denotes decreasing. Significant p-values are indicated in Bold.